FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367175083> ?p ?o ?g. }

• W4367175083 endingPage "2763" @default.
• W4367175083 startingPage "2753" @default.
• W4367175083 abstract "In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m2, cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines (PL). One hundred and ninety-seven patients were included and randomized 1:1 to receive KCd (97 patients) or Kd (100 patients) in 28-day cycles until progressive disease or unacceptable toxicity occurred. Patient median age was 70 years, and the median number of PL was one (range, 1-3). More than 90% of patients had previously been exposed to proteasome inhibitors, approximetely 70% to immunomodulators, and approximetely 50% were refractory to their last line (mainly lenalidomide) in both groups. After a median follow-up of 37 months, median progression-free survival (PFS) was 19.1 and 16.6 months in KCd and Kd, respectively (P=0.577). Of note, in the post hoc analysis of the lenalidomide-refractory population, the addition of cyclophosphamide to Kd resulted in a significant benefit in terms of PFS: 18.4 versus 11.3 months (hazard ratio =1.7, 95% confidence interval: 1.1-2.7; P=0.043). The overall response rate and the percentage of patients who achieved complete response was around 70% and 20% in both groups. The addition of cyclophosphamide to Kd did not result in any safety signal, except for severe infections (7% vs. 2%). In conclusion, the combination of cyclophosphamide with Kd 70 mg/m2 weekly does not improve outcomes as compared with Kd alone in RRMM after 1-3 PL, but a significant benefit in PFS was observed with the triplet combination in the lenalidomide-refractory population. The administration of weekly carfilzomib 70 mg/m2 was safe and convenient, and, overall, the toxicity was manageable in both arms." @default.
• W4367175083 created "2023-04-28" @default.
• W4367175083 creator A5008759843 @default.
• W4367175083 creator A5014715028 @default.
• W4367175083 creator A5015898454 @default.
• W4367175083 creator A5016479494 @default.
• W4367175083 creator A5020420490 @default.
• W4367175083 creator A5024244442 @default.
• W4367175083 creator A5026204359 @default.
• W4367175083 creator A5029159537 @default.
• W4367175083 creator A5030389092 @default.
• W4367175083 creator A5031837957 @default.
• W4367175083 creator A5033664970 @default.
• W4367175083 creator A5034182883 @default.
• W4367175083 creator A5035866456 @default.
• W4367175083 creator A5035883773 @default.
• W4367175083 creator A5036725271 @default.
• W4367175083 creator A5049205706 @default.
• W4367175083 creator A5053642352 @default.
• W4367175083 creator A5054952877 @default.
• W4367175083 creator A5057834186 @default.
• W4367175083 creator A5058168384 @default.
• W4367175083 creator A5062126850 @default.
• W4367175083 creator A5064147442 @default.
• W4367175083 creator A5068331571 @default.
• W4367175083 creator A5068988731 @default.
• W4367175083 creator A5075341471 @default.
• W4367175083 creator A5077430940 @default.
• W4367175083 creator A5083734088 @default.
• W4367175083 date "2023-04-27" @default.
• W4367175083 modified "2023-10-18" @default.
• W4367175083 title "Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients" @default.
• W4367175083 cites W1773271542 @default.
• W4367175083 cites W1985864219 @default.
• W4367175083 cites W2015880063 @default.
• W4367175083 cites W2039217634 @default.
• W4367175083 cites W2056236957 @default.
• W4367175083 cites W2066800926 @default.
• W4367175083 cites W2111159843 @default.
• W4367175083 cites W2134618140 @default.
• W4367175083 cites W2144728882 @default.
• W4367175083 cites W2193716145 @default.
• W4367175083 cites W2274241277 @default.
• W4367175083 cites W2465965969 @default.
• W4367175083 cites W2486629951 @default.
• W4367175083 cites W2489715554 @default.
• W4367175083 cites W2579739608 @default.
• W4367175083 cites W2749746182 @default.
• W4367175083 cites W2755364495 @default.
• W4367175083 cites W2805341297 @default.
• W4367175083 cites W2945852816 @default.
• W4367175083 cites W2979802397 @default.
• W4367175083 cites W3133701599 @default.
• W4367175083 cites W3158532759 @default.
• W4367175083 cites W3164708987 @default.
• W4367175083 cites W3170038569 @default.
• W4367175083 cites W4200193150 @default.
• W4367175083 cites W4280488597 @default.
• W4367175083 doi "https://doi.org/10.3324/haematol.2022.282490" @default.
• W4367175083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37102598" @default.
• W4367175083 hasPublicationYear "2023" @default.
• W4367175083 type Work @default.
• W4367175083 citedByCount "0" @default.
• W4367175083 crossrefType "journal-article" @default.
• W4367175083 hasAuthorship W4367175083A5008759843 @default.
• W4367175083 hasAuthorship W4367175083A5014715028 @default.
• W4367175083 hasAuthorship W4367175083A5015898454 @default.
• W4367175083 hasAuthorship W4367175083A5016479494 @default.
• W4367175083 hasAuthorship W4367175083A5020420490 @default.
• W4367175083 hasAuthorship W4367175083A5024244442 @default.
• W4367175083 hasAuthorship W4367175083A5026204359 @default.
• W4367175083 hasAuthorship W4367175083A5029159537 @default.
• W4367175083 hasAuthorship W4367175083A5030389092 @default.
• W4367175083 hasAuthorship W4367175083A5031837957 @default.
• W4367175083 hasAuthorship W4367175083A5033664970 @default.
• W4367175083 hasAuthorship W4367175083A5034182883 @default.
• W4367175083 hasAuthorship W4367175083A5035866456 @default.
• W4367175083 hasAuthorship W4367175083A5035883773 @default.
• W4367175083 hasAuthorship W4367175083A5036725271 @default.
• W4367175083 hasAuthorship W4367175083A5049205706 @default.
• W4367175083 hasAuthorship W4367175083A5053642352 @default.
• W4367175083 hasAuthorship W4367175083A5054952877 @default.
• W4367175083 hasAuthorship W4367175083A5057834186 @default.
• W4367175083 hasAuthorship W4367175083A5058168384 @default.
• W4367175083 hasAuthorship W4367175083A5062126850 @default.
• W4367175083 hasAuthorship W4367175083A5064147442 @default.
• W4367175083 hasAuthorship W4367175083A5068331571 @default.
• W4367175083 hasAuthorship W4367175083A5068988731 @default.
• W4367175083 hasAuthorship W4367175083A5075341471 @default.
• W4367175083 hasAuthorship W4367175083A5077430940 @default.
• W4367175083 hasAuthorship W4367175083A5083734088 @default.
• W4367175083 hasBestOaLocation W43671750831 @default.
• W4367175083 hasConcept C121332964 @default.
• W4367175083 hasConcept C126322002 @default.
• W4367175083 hasConcept C141071460 @default.
• W4367175083 hasConcept C142424586 @default.
• W4367175083 hasConcept C168563851 @default.
• W4367175083 hasConcept C207103383 @default.

• next